Managing acute intracerebral hemorrhage (ICH) requires balancing quick interventions with patient safety. When a patient presents with an acute stroke secondary to a parenchymal bleed—such as a basal ganglia hemorrhage—controlling systemic blood pressure is a primary initial objective.
Blood Pressure Targets
Current NICE guidelines (NG128) recommend aiming for a systolic blood pressure (SBP) target of 130 to 140 mmHg within 1 hour of starting treatment, maintaining this level for at least 7 days.
Presentation < 6 Hours: Rapid blood pressure lowering to the 130–140 mmHg target is recommended for patients presenting within 6 hours of symptom onset with an initial SBP between 150 mmHg and 220 mmHg.
Presentation > 6 Hours or SBP > 220 mmHg: Rapid BP lowering to this target should also be considered.
Clinical Context: INTERACT-2 vs. ATACH-2
The target range of 130–140 mmHg reflects findings from major clinical trials:
INTERACT-2 demonstrated the benefits of moderate, rapid BP reduction
. ATACH-2 highlighted that overly aggressive BP reduction (below 130 mmHg) increased the risk of renal adverse events and hypotensive episodes requiring corrective intervention
.
Neurosurgical and Diagnostic Considerations
Neurosurgery: In deep bleeds (e.g., basal ganglia) lacking significant edema, mass effect, or intraventricular extension, immediate neurosurgical evacuation is generally not indicated
. CT Angiography (CTA): Urgent CTA helps identify vascular malformations
. However, it may be omitted in older patients (>50 years) with deep-seated hemorrhages, a history of hypertension, and microvascular changes on non-contrast CT . Hemostatic Therapy: While tranexamic acid shows a modest reduction in hematoma expansion, evidence does not yet support routine use to improve long-term functional outcomes
.
